1 completed, 1 recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow End Stage Kidney Disease: new trials by email Literature Review of End Stage Kidney Disease trials Research Report on End Stage Kidney Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) CSL300, Placebo - End Stage Kidney Disease | Phase 2 / Phase 3 | Recruiting | CSL Behring | 3110 | 2024-04-27 | 2026-09-21 |
| Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation IdeS - End Stage Kidney Disease | Phase 2 | Completed | Hansa Biopharma AB | 10 | 2015-06-01 | 2018-01-08 |
Kidney Failure, Chronic (2) · Atherosclerosis (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Myocardial Infarction (1) · Peripheral Arterial Disease (1)
Chronic Disease (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Renal Insufficiency (2) · Renal Insufficiency, Chronic (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiovascular Diseases (1)
clazakizumab (1)
CSL Behring (1) · Hansa Biopharma AB (1)
Sweden (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1)